Back Bay Life Science Advisors published a new Pharmaceutical Executive feature discussing the evolving IBD treatment landscape, drawing on insights from Back Bay's recent white paper with Nimbus Therapeutics.
Published
Signal category
Research & Knowledge
Quote
“Back Bay’s recent white paper with Nimbus Therapeutics that explores physician perspectives on current treatments, the limitations of JAK inhibitors and the potential for next-generation oral therapies to offer biologic-like efficacy with an improved safety profile”
— Back Bay Life Science Advisors team
Company
Back Bay Life Science Advisors
Strategic guidance and investment banking for healthcare companies and their investors. DNB//Back Bay Partnership
- Industry
- Strategic Management Services
- Location
- Boston, US
- Company size
- 34 employees
Back Bay Life Science Advisors offers integrated strategy consulting and investment banking execution for the life sciences. We guide biotech, pharmaceutical, and medical technology companies and their investors on development, commercialization, growth, and maintenance of market share. Back Bay provides clear and unbiased advice and execution for the critical decisions that drive value. In 2023, Back Bay entered a strategic partnership with DNB Bank to provide healthcare companies with strategic guidance, M&A and partnering support and execution and capabilities in global capital markets and investment and commercial banking. Together, as an international collaboration, DNB and Back Bay Life Science Advisors offer unique support to companies along the full continuum of life science and healthcare development. Learn more: https://bit.ly/3MUKD9q
Founded 2010